Henricks, Linda M <br/><br/>
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  01 2019 
 - 60-67 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2018.11.010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Capecitabine--administration & dosage<br/>Costs and Cost Analysis<br/>Dihydrouracil Dehydrogenase (NADP)--genetics<br/>Fluorouracil--administration & dosage<br/>Genetic Testing<br/>Genotype<br/>Humans<br/>Neoplasms--drug therapy<br/>Polymorphism, Genetic<br/>Precision Medicine--economics<br/>Prognosis<br/>Prospective Studies